Clindamycin hydrochloride preparation for injection and preparation method thereof

A technology for clindamycin hydrochloride and injection, which is applied in the direction of medical preparations with non-active ingredients, medical preparations containing active ingredients, and pharmaceutical formulas, and can solve the problems of no relative drug advantages, adverse drug reactions, and ineffectiveness. Control the drug release rate and other issues to achieve the effects of reducing adverse reactions, improving bioavailability, and maintaining blood drug concentration

Active Publication Date: 2013-12-11
WUHAN PUSHENG PHARMA
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] CN1830452A discloses "A Preparation Method of Clindamycin Hydrochloride Freeze-dried Powder Injection", the product in this method does not increase the drug activity of the drug, but is simply freeze-dried, and has no relative drug advantage
However, once the alkyl cyanoacrylate in the preparation degrades rapidly in the body, the release rate of the drug cannot be effectively controlled. Once the peak-valley phenomenon occurs, it will inevitably cause adverse drug reactions.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Clindamycin hydrochloride preparation for injection and preparation method thereof
  • Clindamycin hydrochloride preparation for injection and preparation method thereof
  • Clindamycin hydrochloride preparation for injection and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] formula:

[0020]

[0021] Preparation:

[0022] ①Dissolve clindamycin hydrochloride in 2000ml of water for injection, and stir at room temperature of 25°C until clear to obtain solution A;

[0023] ② Sodium hydroxide and hydrochloric acid are configured into a clear solution with a concentration of 10mol / L, and the pH value is adjusted to 5.8 to obtain solution B;

[0024] ③ Fe 3 o 4 Mix the magnetic powder and carboxymethyl glucose, add liquid paraffin covering the mixture, add one-third of the amount of glutaraldehyde to the magnetic powder and react for 30 minutes while stirring at room temperature at 40°C, adjust the pH value of the solution to 9, continue the reaction for 30 minutes, and cool , washed and dried to obtain coated nano-Fe 3 o 4 Particle carboxymethylglucose magnetic microspheres C;

[0025] ④ Mix solution A and solution B evenly, add coated nano-Fe 3 o 4 Particle carboxymethylglucose magnetic microspheres C were stirred at room temperature...

Embodiment 2

[0028] formula:

[0029]

[0030] The preparation method is the same as in Example 1.

Embodiment 3

[0032] formula:

[0033]

[0034]

[0035] The preparation method is the same as in Example 1.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
Login to view more

Abstract

The invention discloses a clindamycin hydrochloride preparation for injection and a preparation method thereof. The preparation is prepared from clindamycin hydrochloride and auxiliary materials such as Fe3O4 magnetic powder and carboxymethyl glucose. In the preparation process, Fe3O4 magnetic powder and carboxymethyl glucose mixed are stable in property to easily form microballoons with certain strength and can be fully encapsulated or the medicine completely enters into a carrier framework, relatively. After injection, the medicine can be reasonably released in human body, so that the pharmacological activity of the medicine is maintained and the bioavailability of the medicine is improved. Meanwhile, the time of deliveries of medicines to be used for a long time can be reduced due to the sustained-release preparation, so that balance of blood concentration can be maintained, the peak valley phenomenon is avoided, and untoward effects of the medicine are reduced. In addition, the iron content of the carrier in the preparation does not affect normal total iron supplementing amount of the patient, and magnetic particles can be safely discharged outside the human body through normal excretion of the human body.

Description

technical field [0001] The invention belongs to a pharmaceutical preparation, in particular to a clindamycin hydrochloride preparation for injection and a preparation method thereof. Background technique [0002] Clindamycin Hydrochloride (Clindamycin Hydrochloride) chemical name 6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-7(S)-chloro-6, 7,8-trideoxy-L-threo-α-D-galactosoctopyranoside hydrochloride is a derivative obtained after the hydroxyl group at the 7-position of lincomycin is replaced by chlorine, which belongs to antibiotic drugs. Synthesized by Magerlein et al. in 1966, its antibacterial activity is 4-8 times stronger than that of lincomycin. Clindamycin hydrochloride has antibacterial activity against gram-positive aerobic bacteria, streptococcus and staphylococcus, and also has antibacterial activity against various anaerobic bacteria, chlamydia, mycoplasma, plasmodium and toxoplasma. The 50s subunit of the ribosome inhibits the synthesis of bac...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/19A61K31/7056A61K47/02A61K47/26A61P31/04A61P31/00A61P33/02A61P33/06
Inventor 刘昔平徐林华刘浏梅媛陈杰枫王萍
Owner WUHAN PUSHENG PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap